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denosine at Reperfusion
Conundrum Ready to Be Resolved*
ichael V. Cohen, MD, FACC,
ames M. Downey, PHD
obile, Alabama
he purine nucleoside adenosine is the parent compound of
he ubiquitous intracellular high-energy compound adeno-
ine triphosphate (ATP). During aerobic metabolism the
ntracellular adenosine concentration is only 30 to 300 nM
ecause adenosine is being used to synthesize ATP. How-
ver, during anaerobic metabolism cellular ATP stores are
epleted and the adenosine concentration increases 100-
old to as much as 10 M. Adenosine itself has vasodilatory
nd negative chronotropic effects and thus causes hypoten-
ion and bradycardia when injected into the circulation. The
atter effect has been used to great advantage in the acute
reatment of supraventricular arrhythmias. Its use as a
ardioprotective agent in both experimental animals and
umans, however, has had a checkered history.
See page 709
After the initial report by Murry et al. (1) in 1986 of the
henomenon of ischemic preconditioning (IPC), several
aboratories began to assess possible mechanisms. An early
bservation by Liu et al. (2) suggested that IPC was
ependent on adenosine, presumably released by ischemic
ells, which would bind to its sarcolemmal Gi protein-
oupled receptor to trigger downstream intracellular signal-
ng and eventual activation of the hypothesized cardiopro-
ective end-effector. Although the signaling is much more
omplicated than these investigators first imagined, even at
he level of the very initial agonist-receptor binding, aden-
sine retained its great appeal as a promising trigger of
ardioprotection, and several investigators imagined that
xogenous adenosine might have the same result, thus leading
o development of an effective strategy for clinical use.
Forman’s group (3–7) pioneered investigation of the
otential of exogenous adenosine to salvage ischemic myo-
ardium. In a series of reports in various experimental
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Departments of Physiology and Medicine, College of Medicine,
niversity of South Alabama, Mobile, Alabama.nimal models, these researchers claimed that an intrave-
ous infusion of adenosine could indeed reduce the extent of
yocardial infarction. However, other investigative groups
ere unable to duplicate these results (8–10). The meticu-
ous protocol of Vander Heide and Reimer (9), which
arefully duplicated that used by Forman’s group, failed to
roduce any benefit of intravenous adenosine on infarct size
n dogs. We also tested exogenous adenosine in rabbits in a
omparable ischemia/reperfusion protocol (11). None of the
ntravenous doses of adenosine that we infused had any
alutary effect. We were limited in the amount of adenosine
hat could be infused because of its profound hypotensive
ffect, and perhaps a higher intracoronary dose would have
rotected the heart. Despite these contradictory pre-clinical
esults, 2 large clinical studies have examined the effect of
denosine infusion in patients with acute myocardial infarc-
ion (12,13). The results have been mixed.
In this issue of the Journal, Takahama et al. (14) have
eveloped a new technique for the delivery of adenosine to
schemic hearts that circumvents the problem noted above.
hey encapsulated adenosine in polyethylene glycol-coated
PEGylated) liposomes. These investigators infused these
iposomes into rats for 10 min starting 5 min before release
f a left coronary artery occlusion. The liposomes were
ound to be extensively taken up by the ischemic myocar-
ium, but curiously not by nonischemic myocardium. Re-
arkably PEGylated liposomal adenosine at a dose of 450
g/kg/min had no significant effects on either mean blood
ressure or heart rate, whereas the same dose of free
denosine lowered mean blood pressure by 25.4%. Thus,
hey concluded that it is possible to intravenously administer
igh doses of adenosine to the ischemic heart without
ffecting hemodynamics.
Takahama et al. (14) then measured infarct size in rats
reated with PEGylated liposomal adenosine. An infusion
f 450 g/kg/min reduced infarct size from 53.2% of the
isk zone in untreated hearts to 29.5% (p 0.05). Although
t will be important for other investigators to confirm these
esults, it is likely that high-dose adenosine can be cardio-
rotective if complicating hypotension and bradycardia can
e avoided.
Although up to now the ability of authentic adenosine to
e cardioprotective was controversial, there is less dispute
egarding whether adenosine receptor subtypes can protect
he heart at the time of reperfusion. The receptor-selective
denosine analog BAY 60-6583, a highly selective adeno-
ine A2b agonist, reduced infarction in rabbit hearts when
nfused minutes before reperfusion (15). Consistent with
his observation was the determination that the protective
ffect of ischemic post-conditioning was abrogated by a
pecific A2b antagonist (16). Although Kin et al. (17)
eported that an A2a antagonist blocked post-conditioning’s
rotection, the selectivity of that agent is probably not
ufficient to exclude an A2b mechanism. The A2a-selective
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18). Adenosine is quickly metabolized in the tissues, and it
ay be that authentic adenosine simply cannot achieve a
ufficiently high concentration to populate the receptors on
he cardiomyocyte when delivered by an intravenous route.
he analogs are stable and pass intact through the capillary
ndothelium.
Takahama et al. (14) administered liposomal adenosine
o hearts and also infused either the nonselective adenosine
eceptor antagonist 8-(p-sulfophenyl) theophylline (8-SPT)
r 1 of the selective adenosine A1, A2a, A2b, or A3 receptor
ubtype antagonists. Not surprisingly, 8-SPT blocked pro-
ection confirming involvement of an adenosine receptor.
hat is puzzling is that an antagonist to each of the 4
denosine receptor subtypes also attenuated protection from
iposomal adenosine. It seems unlikely that all 4 subtypes
ould be involved in protection. This implausible result
ould even reflect false-positive observations related to
he very wide range of infarct sizes in some groups (3% to
8% and 16% to 65% infarction of the ischemic zone in
he liposomal adenosine and liposomal adenosine plus
RS1754 groups, respectively). Such wide ranges make
tatistical significance difficult to determine, especially when
he numbers of experiments are small and a normal distri-
ution has not been achieved. Hence, the identity of the
pecific adenosine receptor subtype or subtypes involved in
hese studies has not yet been fully determined and addi-
ional experimental studies are probably warranted.
Thus, a novel delivery vehicle for adenosine has been
escribed that minimizes adverse hemodynamic effects and
ermits delivery of large amounts of the drug to ischemic
issue. Although the exact pathways involved in the protection
emain obscure, the clinical implications are obvious. The
ntravenous route of administration simplifies use of this
denosine preparation, and adenosine is clearly not toxic. This
iposomal adenosine can be added to a growing list of drugs
hat seem to limit infarct size in animal models when admin-
stered at the time of reperfusion (19).
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